KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Net Income (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Net Income for 18 consecutive years, with -$92.5 million as the latest value for Q1 2026.

  • For Q1 2026, Net Income rose 37.03% year-over-year to -$92.5 million; the TTM value through Mar 2026 reached $54.2 million, up 1922.5%, while the annual FY2025 figure was -$207000.0, 103.04% down from the prior year.
  • Net Income hit -$92.5 million in Q1 2026 for Ionis Pharmaceuticals, down from $151.8 million in the prior quarter.
  • Across five years, Net Income topped out at $356.4 million in Q4 2024 and bottomed at -$147.4 million in Q3 2023.
  • Average Net Income over 5 years is -$42.5 million, with a median of -$85.2 million recorded in 2023.
  • Year-over-year, Net Income plummeted 213.58% in 2023 and then surged 3661.85% in 2024.
  • Ionis Pharmaceuticals' Net Income stood at -$52.5 million in 2022, then soared by 80.93% to -$10.0 million in 2023, then soared by 3661.85% to $356.4 million in 2024, then crashed by 57.41% to $151.8 million in 2025, then plummeted by 160.96% to -$92.5 million in 2026.
  • According to Business Quant data, Net Income over the past three periods came in at -$92.5 million, $151.8 million, and -$128.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.